Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment?
To prospectively compare combined radiofrequency ablation and transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of small (< or =3 cm) hepatocellular carcinomas (HCCs). The ethics committee of the study institution approved the study protocol. Wri...
Gespeichert in:
| Veröffentlicht in: | Radiology 2009-09, Vol.252 (3), p.905-913 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 913 |
|---|---|
| container_issue | 3 |
| container_start_page | 905 |
| container_title | Radiology |
| container_volume | 252 |
| creator | SHIBATA, Toshiya ISODA, Hiroyoshi HIROKAWA, Yusuke ARIZONO, Shigeki SHIMADA, Kotaro TOGASHI, Kaori |
| description | To prospectively compare combined radiofrequency ablation and transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of small (< or =3 cm) hepatocellular carcinomas (HCCs).
The ethics committee of the study institution approved the study protocol. Written informed consent was obtained from all patients at enrollment. Eighty-nine patients with 93 HCC nodules 0.8-3.0 cm (mean +/- standard deviation, 1.7 cm +/- 0.5) in diameter were randomly treated with combined radiofrequency ablation and TACE (46 patients with 49 nodules) or with radiofrequency ablation alone (43 patients with 44 nodules). The patients were followed up for 9-68 months (mean +/- standard deviation, 30.4 months +/- 14.0). Rates of local tumor progression, overall survival, local progression-free survival, and event-free survival were evaluated by using the Kaplan-Meier method.
The 1-, 2-, 3-, and 4-year rates of local tumor progression, overall survival, local progression-free survival, and recurrence-free survival were as follows: Local tumor progression rates were 14.4%, 17.6%, 17.6%, and 17.6%, respectively, in the combined treatment group and 11.4%, 14.4%, 14.4%, and 14.4%, respectively, in the radiofrequency ablation group (P = .797). Overall survival rates were 100%, 100%, 84.8%, and 72.7%, respectively, in the combined treatment group and 100%, 88.8%, 84.5%, and 74.0%, respectively, in the radiofrequency ablation group (P = .515). Local progression-free survival rates were 84.6%, 81.1%, 69.7%, and 55.8%, respectively, in the combined treatment group and 88.4%, 74.1%, 74.1%, and 61.7%, respectively, in the radiofrequency ablation group (P = .934). Event-free survival rates were 71.3%, 59.9%, 48.8%, and 36.6%, respectively, in the combined treatment group and 74.3%, 52.4%, 29.7%, and 29.7%, respectively, in the radiofrequency ablation group (P = .365).
Combined radiofrequency ablation plus TACE and radiofrequency ablation alone have equivalent effectiveness for the treatment of small (< or =3 cm) HCCs, so the combination treatment may not be necessary. |
| doi_str_mv | 10.1148/radiol.2523081676 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67620207</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67620207</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-95d6da7fd6b0be3e801eac175397294192b80d3814ea902b8f874494363b31723</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS1ERaeFB2CDvIFdWv8kscMGjaLSVmqFBGUd3SQ3GiP_DLYHVB6rT4hHM6IrNr6y9J1zr84h5C1nF5zX-jLCbIK9EI2QTPNWtS_IijdCVVzy5iVZMSZlpWvenZKzlH4wxutGq1fklHdNoWu1Ik_fHFhLb3ALOUxo7c5CpD3Eyfjg4CO9TfTrfs0S8ecO_fRI16OFbIKnfXCj8TjT3yZv6EMEnybIG8wY6TqW14Cl_QZdQDcGa_4cZPchIr1aFpyy-YU0b8D_d8XaBo90CbHYI2SHPn96TU4WsAnfHOc5-f756qG_qe6-XN_267tqkqLLVdfM7QxqmduRjShRM44wcdXITomuhCJGzWapeY3QsfJZtKrrrpatHCVXQp6TDwffbQzlrpQHZ9I-IvAYdmkoCQommCogP4BTDClFXIZtNA7i48DZsC9qOBQ1PBdVNO-O5rvR4fysODZTgPdHAEqqdinpTib94wTXQupy5V-sy6CQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67620207</pqid></control><display><type>article</type><title>Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>SHIBATA, Toshiya ; ISODA, Hiroyoshi ; HIROKAWA, Yusuke ; ARIZONO, Shigeki ; SHIMADA, Kotaro ; TOGASHI, Kaori</creator><creatorcontrib>SHIBATA, Toshiya ; ISODA, Hiroyoshi ; HIROKAWA, Yusuke ; ARIZONO, Shigeki ; SHIMADA, Kotaro ; TOGASHI, Kaori</creatorcontrib><description>To prospectively compare combined radiofrequency ablation and transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of small (< or =3 cm) hepatocellular carcinomas (HCCs).
The ethics committee of the study institution approved the study protocol. Written informed consent was obtained from all patients at enrollment. Eighty-nine patients with 93 HCC nodules 0.8-3.0 cm (mean +/- standard deviation, 1.7 cm +/- 0.5) in diameter were randomly treated with combined radiofrequency ablation and TACE (46 patients with 49 nodules) or with radiofrequency ablation alone (43 patients with 44 nodules). The patients were followed up for 9-68 months (mean +/- standard deviation, 30.4 months +/- 14.0). Rates of local tumor progression, overall survival, local progression-free survival, and event-free survival were evaluated by using the Kaplan-Meier method.
The 1-, 2-, 3-, and 4-year rates of local tumor progression, overall survival, local progression-free survival, and recurrence-free survival were as follows: Local tumor progression rates were 14.4%, 17.6%, 17.6%, and 17.6%, respectively, in the combined treatment group and 11.4%, 14.4%, 14.4%, and 14.4%, respectively, in the radiofrequency ablation group (P = .797). Overall survival rates were 100%, 100%, 84.8%, and 72.7%, respectively, in the combined treatment group and 100%, 88.8%, 84.5%, and 74.0%, respectively, in the radiofrequency ablation group (P = .515). Local progression-free survival rates were 84.6%, 81.1%, 69.7%, and 55.8%, respectively, in the combined treatment group and 88.4%, 74.1%, 74.1%, and 61.7%, respectively, in the radiofrequency ablation group (P = .934). Event-free survival rates were 71.3%, 59.9%, 48.8%, and 36.6%, respectively, in the combined treatment group and 74.3%, 52.4%, 29.7%, and 29.7%, respectively, in the radiofrequency ablation group (P = .365).
Combined radiofrequency ablation plus TACE and radiofrequency ablation alone have equivalent effectiveness for the treatment of small (< or =3 cm) HCCs, so the combination treatment may not be necessary.</description><identifier>ISSN: 0033-8419</identifier><identifier>EISSN: 1527-1315</identifier><identifier>DOI: 10.1148/radiol.2523081676</identifier><identifier>PMID: 19567647</identifier><identifier>CODEN: RADLAX</identifier><language>eng</language><publisher>Oak Brook, IL: Radiological Society of North America</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma, Hepatocellular - surgery ; Carcinoma, Hepatocellular - therapy ; Catheter Ablation - methods ; Chemoembolization, Therapeutic - methods ; Chi-Square Distribution ; Disease Progression ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Liver Neoplasms - surgery ; Liver Neoplasms - therapy ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Other treatments ; Proportional Hazards Models ; Prospective Studies ; Radiography, Interventional ; Statistics, Nonparametric ; Survival Rate ; Tomography, X-Ray Computed ; Treatment. General aspects ; Tumors</subject><ispartof>Radiology, 2009-09, Vol.252 (3), p.905-913</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-95d6da7fd6b0be3e801eac175397294192b80d3814ea902b8f874494363b31723</citedby><cites>FETCH-LOGICAL-c329t-95d6da7fd6b0be3e801eac175397294192b80d3814ea902b8f874494363b31723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21823872$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19567647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHIBATA, Toshiya</creatorcontrib><creatorcontrib>ISODA, Hiroyoshi</creatorcontrib><creatorcontrib>HIROKAWA, Yusuke</creatorcontrib><creatorcontrib>ARIZONO, Shigeki</creatorcontrib><creatorcontrib>SHIMADA, Kotaro</creatorcontrib><creatorcontrib>TOGASHI, Kaori</creatorcontrib><title>Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment?</title><title>Radiology</title><addtitle>Radiology</addtitle><description>To prospectively compare combined radiofrequency ablation and transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of small (< or =3 cm) hepatocellular carcinomas (HCCs).
The ethics committee of the study institution approved the study protocol. Written informed consent was obtained from all patients at enrollment. Eighty-nine patients with 93 HCC nodules 0.8-3.0 cm (mean +/- standard deviation, 1.7 cm +/- 0.5) in diameter were randomly treated with combined radiofrequency ablation and TACE (46 patients with 49 nodules) or with radiofrequency ablation alone (43 patients with 44 nodules). The patients were followed up for 9-68 months (mean +/- standard deviation, 30.4 months +/- 14.0). Rates of local tumor progression, overall survival, local progression-free survival, and event-free survival were evaluated by using the Kaplan-Meier method.
The 1-, 2-, 3-, and 4-year rates of local tumor progression, overall survival, local progression-free survival, and recurrence-free survival were as follows: Local tumor progression rates were 14.4%, 17.6%, 17.6%, and 17.6%, respectively, in the combined treatment group and 11.4%, 14.4%, 14.4%, and 14.4%, respectively, in the radiofrequency ablation group (P = .797). Overall survival rates were 100%, 100%, 84.8%, and 72.7%, respectively, in the combined treatment group and 100%, 88.8%, 84.5%, and 74.0%, respectively, in the radiofrequency ablation group (P = .515). Local progression-free survival rates were 84.6%, 81.1%, 69.7%, and 55.8%, respectively, in the combined treatment group and 88.4%, 74.1%, 74.1%, and 61.7%, respectively, in the radiofrequency ablation group (P = .934). Event-free survival rates were 71.3%, 59.9%, 48.8%, and 36.6%, respectively, in the combined treatment group and 74.3%, 52.4%, 29.7%, and 29.7%, respectively, in the radiofrequency ablation group (P = .365).
Combined radiofrequency ablation plus TACE and radiofrequency ablation alone have equivalent effectiveness for the treatment of small (< or =3 cm) HCCs, so the combination treatment may not be necessary.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Catheter Ablation - methods</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Chi-Square Distribution</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver Neoplasms - therapy</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other treatments</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Radiography, Interventional</subject><subject>Statistics, Nonparametric</subject><subject>Survival Rate</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment. General aspects</subject><subject>Tumors</subject><issn>0033-8419</issn><issn>1527-1315</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS1ERaeFB2CDvIFdWv8kscMGjaLSVmqFBGUd3SQ3GiP_DLYHVB6rT4hHM6IrNr6y9J1zr84h5C1nF5zX-jLCbIK9EI2QTPNWtS_IijdCVVzy5iVZMSZlpWvenZKzlH4wxutGq1fklHdNoWu1Ik_fHFhLb3ALOUxo7c5CpD3Eyfjg4CO9TfTrfs0S8ecO_fRI16OFbIKnfXCj8TjT3yZv6EMEnybIG8wY6TqW14Cl_QZdQDcGa_4cZPchIr1aFpyy-YU0b8D_d8XaBo90CbHYI2SHPn96TU4WsAnfHOc5-f756qG_qe6-XN_267tqkqLLVdfM7QxqmduRjShRM44wcdXITomuhCJGzWapeY3QsfJZtKrrrpatHCVXQp6TDwffbQzlrpQHZ9I-IvAYdmkoCQommCogP4BTDClFXIZtNA7i48DZsC9qOBQ1PBdVNO-O5rvR4fysODZTgPdHAEqqdinpTib94wTXQupy5V-sy6CQ</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>SHIBATA, Toshiya</creator><creator>ISODA, Hiroyoshi</creator><creator>HIROKAWA, Yusuke</creator><creator>ARIZONO, Shigeki</creator><creator>SHIMADA, Kotaro</creator><creator>TOGASHI, Kaori</creator><general>Radiological Society of North America</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090901</creationdate><title>Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment?</title><author>SHIBATA, Toshiya ; ISODA, Hiroyoshi ; HIROKAWA, Yusuke ; ARIZONO, Shigeki ; SHIMADA, Kotaro ; TOGASHI, Kaori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-95d6da7fd6b0be3e801eac175397294192b80d3814ea902b8f874494363b31723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Catheter Ablation - methods</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Chi-Square Distribution</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver Neoplasms - therapy</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other treatments</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Radiography, Interventional</topic><topic>Statistics, Nonparametric</topic><topic>Survival Rate</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment. General aspects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHIBATA, Toshiya</creatorcontrib><creatorcontrib>ISODA, Hiroyoshi</creatorcontrib><creatorcontrib>HIROKAWA, Yusuke</creatorcontrib><creatorcontrib>ARIZONO, Shigeki</creatorcontrib><creatorcontrib>SHIMADA, Kotaro</creatorcontrib><creatorcontrib>TOGASHI, Kaori</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHIBATA, Toshiya</au><au>ISODA, Hiroyoshi</au><au>HIROKAWA, Yusuke</au><au>ARIZONO, Shigeki</au><au>SHIMADA, Kotaro</au><au>TOGASHI, Kaori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment?</atitle><jtitle>Radiology</jtitle><addtitle>Radiology</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>252</volume><issue>3</issue><spage>905</spage><epage>913</epage><pages>905-913</pages><issn>0033-8419</issn><eissn>1527-1315</eissn><coden>RADLAX</coden><abstract>To prospectively compare combined radiofrequency ablation and transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of small (< or =3 cm) hepatocellular carcinomas (HCCs).
The ethics committee of the study institution approved the study protocol. Written informed consent was obtained from all patients at enrollment. Eighty-nine patients with 93 HCC nodules 0.8-3.0 cm (mean +/- standard deviation, 1.7 cm +/- 0.5) in diameter were randomly treated with combined radiofrequency ablation and TACE (46 patients with 49 nodules) or with radiofrequency ablation alone (43 patients with 44 nodules). The patients were followed up for 9-68 months (mean +/- standard deviation, 30.4 months +/- 14.0). Rates of local tumor progression, overall survival, local progression-free survival, and event-free survival were evaluated by using the Kaplan-Meier method.
The 1-, 2-, 3-, and 4-year rates of local tumor progression, overall survival, local progression-free survival, and recurrence-free survival were as follows: Local tumor progression rates were 14.4%, 17.6%, 17.6%, and 17.6%, respectively, in the combined treatment group and 11.4%, 14.4%, 14.4%, and 14.4%, respectively, in the radiofrequency ablation group (P = .797). Overall survival rates were 100%, 100%, 84.8%, and 72.7%, respectively, in the combined treatment group and 100%, 88.8%, 84.5%, and 74.0%, respectively, in the radiofrequency ablation group (P = .515). Local progression-free survival rates were 84.6%, 81.1%, 69.7%, and 55.8%, respectively, in the combined treatment group and 88.4%, 74.1%, 74.1%, and 61.7%, respectively, in the radiofrequency ablation group (P = .934). Event-free survival rates were 71.3%, 59.9%, 48.8%, and 36.6%, respectively, in the combined treatment group and 74.3%, 52.4%, 29.7%, and 29.7%, respectively, in the radiofrequency ablation group (P = .365).
Combined radiofrequency ablation plus TACE and radiofrequency ablation alone have equivalent effectiveness for the treatment of small (< or =3 cm) HCCs, so the combination treatment may not be necessary.</abstract><cop>Oak Brook, IL</cop><pub>Radiological Society of North America</pub><pmid>19567647</pmid><doi>10.1148/radiol.2523081676</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-8419 |
| ispartof | Radiology, 2009-09, Vol.252 (3), p.905-913 |
| issn | 0033-8419 1527-1315 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67620207 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Hepatocellular - surgery Carcinoma, Hepatocellular - therapy Catheter Ablation - methods Chemoembolization, Therapeutic - methods Chi-Square Distribution Disease Progression Female Gastroenterology. Liver. Pancreas. Abdomen Humans Investigative techniques, diagnostic techniques (general aspects) Liver Neoplasms - surgery Liver Neoplasms - therapy Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Other treatments Proportional Hazards Models Prospective Studies Radiography, Interventional Statistics, Nonparametric Survival Rate Tomography, X-Ray Computed Treatment. General aspects Tumors |
| title | Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A12%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Small%20Hepatocellular%20Carcinoma:%20Is%20Radiofrequency%20Ablation%20Combined%20with%20Transcatheter%20Arterial%20Chemoembolization%20More%20Effective%20than%20Radiofrequency%20Ablation%20Alone%20for%20Treatment?&rft.jtitle=Radiology&rft.au=SHIBATA,%20Toshiya&rft.date=2009-09-01&rft.volume=252&rft.issue=3&rft.spage=905&rft.epage=913&rft.pages=905-913&rft.issn=0033-8419&rft.eissn=1527-1315&rft.coden=RADLAX&rft_id=info:doi/10.1148/radiol.2523081676&rft_dat=%3Cproquest_cross%3E67620207%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67620207&rft_id=info:pmid/19567647&rfr_iscdi=true |